ABSTRACT
Isoniazid (INH) is an important first-line medication for the treatment of tuberculosis. The impact that tuberculosis drug resistance has on treatment outcomes is a topic that is receiving a lot of attention these days because of the rising incidence of INH-resistant cases. Study involves a single group of patients who have been diagnosed with Isoniazid monoresistant tuberculosis. Treatment history and demographic data of the patients were obtained after informed consent. The mutation patterns of isoniazid were observed after multiplex PCR and Line Probe Assay (LPA). A total of 101 patient (M,F) records at the IRL, Puducherry were analyzed. The predominant gene responsible for TB was KATG (67.3%). The KATG Mut1 was a prime mutation observed in the present study population (58.41%). Study showed positive association with males (74%), occupation as coolie (88%), diabetes as comorbidity (33%), pulmonary tuberculosis as the TB site (98.01%), history of previous ATT intake in 43 patients (42.6%), katG mutation (67.3%), katG Mut 1 was the prime mutation (58.4%).The cure rate was high in INH high concentration resistance patients which was statistically significant (p=0.0167). INH monoresistance mutations seen in 64.3% of the patients with katG, compared to inhA (34.65%). Similar to katG mutations, inhA mutations also have MUT1 as their most frequent gene pattern. There is a significant association between males, diabetes, smoking and alcohol addictions were associated with high risk of developing high dose INH monoresistance (katG). High prevalence of recurrent tuberculosis was seen in high dose INH monoresistance tuberculosis. Patients who are microbiologically confirmed pulmonary tuberculosis and diabetes with rifampicin sensitive status needs to be checked for LPA for isoniazid sensitivity status to prevent treatment failure and relapse. It is crucial to understand the gene pattern in each of these patients since these mutations are closely associated to high or low-degree resistance to INH
Competing Interest Statement
none
Funding Statement
the study received no funding as its a postgraduate thesis
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
study used data from TB resgistry. clearance from Insitutional human ethics committee was obtained on 04.03.2021 with number MGMCRI/Res/01/2020/80/IHEC/303
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
the data used for analysis is from drug TB registry from Intemediate reference laboratory, Puducherry